Loading
A phase 1/2 trial of Azacitidine, Pivekimab sunirine and Venetoclax in acute myeloid leukaemia, run by AbbVie, active and no longer recruiting.
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT04086264 by AbbVie, with 218 participants enrolled, started 2019-11-06 and due to reach its primary completion in 2027-02. Interventions recorded: Azacitidine, IMGN632 and Venetoclax.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Pivekimab sunirine, BCL-2 inhibitors, Azacitidine, AbbVie (incl. ImmunoGen, Capstan) and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Shares BCL-2 inhibitors, Azacitidine, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Venetoclax and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/